Meds Don't Cut Trastuzumab-Tied Left Ventricular Remodeling

Share this content:
Meds Don't Cut Trastuzumab-Tied Left Ventricular Remodeling
Meds Don't Cut Trastuzumab-Tied Left Ventricular Remodeling

FRIDAY, Dec. 2, 2016 (HealthDay News) -- For patients with human epidermal growth factor receptor 2-overexpressing (HER2-positive) early breast cancer, perindopril and bisoprolol do not prevent trastuzumab-mediated left ventricular remodeling, according to a study published online Nov. 28 in the Journal of Clinical Oncology.

Edith Pituskin, R.N., Ph.D., from the University of Alberta in Edmonton, Canada, and colleagues conducted a placebo-controlled trial involving patients with HER2-positive early breast cancer. Participants were randomized to receive perindopril (33 patients), bisoprolol (31 patients), or placebo (30 patients) for the duration of trastuzumab adjuvant therapy. Left ventricular volumes and left ventricular ejection fraction (LVEF) were determined by cardiac magnetic resonance imaging at baseline and post-cycle 17.

The researchers found that the drugs were well tolerated, with no serious adverse events reported. The indexed left ventricular end diastolic volume increased in patients treated with perindopril, bisoprolol, and placebo (P = 0.36). The trastuzumab-mediated decline in LVEF was attenuated in bisoprolol-treated patients relative to patients treated with perindopril and placebo in secondary analyses (P = 0.001). On multivariable analysis, perindopril and bisoprolol use independently predicted maintained LVEF.

"Perindopril and bisoprolol were well tolerated in patients with HER2-positive early breast cancer who received trastuzumab and protected against cancer therapy-related declines in LVEF; however, trastuzumab-mediated left ventricular remodeling -- the primary outcome -- was not prevented by these pharmacotherapies," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Trials Highlight Benefits, Risks of Testosterone Treatment

Trials Highlight Benefits, Risks of Testosterone Treatment

While trials show it boosts bone density and lowers anemia risk, heart risks also seen

Exercise Most Important Lifestyle Change for Breast CA Survivors

Exercise Most Important Lifestyle Change for Breast CA ...

Those who exercised were about 40 percent less likely to die from disease, review suggests

CMS Rule Set to Stabilize Small Health Insurance Markets

CMS Rule Set to Stabilize Small Health Insurance ...

Rule includes special enrollment period pre-enrollment verification, flexibility in level of cover

is free, fast, and customized just for you!

Already a member?

Sign In Now »